Opdualag | Nivolumab-Relatlimab Injection

✓ First-in-class dual LAG-3 + PD-1 immune checkpoint combo

✓ Doubled progression-free survival vs nivolumab alone in melanoma

✓ Single IV infusion delivers two synergistic biologics

✓ Re-activates exhausted tumor-infiltrating T-cells

✓ Modern breakthrough cancer immunotherapy

Guaranteed Safe Checkout

Onlinemedex Features:-

Fulfilled-using-ems

Generic Name :	Nivolumab-Relatlimab
Drug class:	PD-1 / LAG-3 Inhibitor Combination
CSA Schedule:	Non-controlled drug
Approval:	FDA approved 2022

BRAND OR GENERIC	GENERIC
STRENGTH	240 mg Nivolumab + 80 mg Relatlimab/20 ml
SELECTED PACKAGE	12 Unit(s), 3 Unit(s), 6 Unit(s), 9 Unit(s)

Reviews

There are no reviews yet.

Be the first to review “Opdualag | Nivolumab-Relatlimab Injection”